1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Endeavor Rockets Ahead With IPF Drug After Phase IIa Results

 
• By Alaric DeArment

The biotech plans to run a Phase II study of ENV-101 in IPF and PPF, followed by a Phase III study that would start in 2026.

• Source: Shutterstock

Endeavor BioMedicines anticipates bringing ENV-101 into another Phase II trial in the second half of the year that would last around six months and then start a Phase III pivotal study, following the presentation over the weekend of positive Phase IIa results in idiopathic pulmonary fibrosis (IPF).

The private biotech presented the Phase IIa data at the American Thoracic Society meeting on 19 May. The study tested the drug in IPF patients over a 12-week period, showing...

Key Takeaways

  • Endeavor BioMedicines presented positive Phase IIa data for ENV-101 in idiopathic pulmonary fibrosis at the American Thoracic Society annual meeting.

  • The drug yielded...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

ASCO: IO Continues Climb To Earlier Use With AstraZeneca’s MATTERHORN, BMS’s NIVOPOSTOP

 
• By Mary Jo Laffler

Data presented at ASCO supports use of AZ’s Imfinzi for perioperative gastric cancer and BMS’s Opdivo for adjuvant treatment of head and neck cancer.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 
• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

ASCO: DESTINY-Breast09 Strong, But May Need Mature OS Data To Change Practice

 
• By Alaric DeArment

Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

More from R&D

Pipeline Watch: Eight Approvals And Nine Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By Kevin Grogan

Buy boosts the French major's immunology pipeline.

Public Health And Innovation: Addressing Gaps, Pharma’s Role

 
• By Anju Ghangurde

Expert panel including Ashok Venkitaraman, Director of the Cancer Science Institute of Singapore, discusses public health challenges and innovations to help address these. Long-acting drugs, intercepting cancer early and “design thinking” by ophthalmologists in India were among the talking points.